Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-747 in T2DM and NAFLD
NCT00501592Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jul 2007
- Primary completion
- Feb 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of obeticholic acid in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), sponsored by Intercept Pharmaceuticals. Started Jul 2007; status: completed.
02
Drugs
obeticholic acid
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT00501592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501592.